

中国药学会系列期刊/《CAJ-CD》规范执行优秀期刊/美国《化学文摘》荷兰SCOPUS等国际著名检索系统收录  
中国中文核心期刊 中国科技核心期刊 中国科学引文数据库来源期刊

CHINESE JOURNAL OF NEW DRUGS

# 中国新药杂志

ISSN 1003-3734  
CN 11-2850/R  
CODEN ZXZHA6



5  
2017  
Vol.26 | No.5

药品临床试验机构资格认证管理平台建设探讨  
药物临床价值评估的主要考虑因素及问题  
胆汁酸及受体与肝癌的研究进展  
玉叶金花化学成分和生物活性的研究进展  
反义寡核苷酸药物流感泰得对大鼠的亚急性毒性观察

www.newdrug.cn

ISSN 1003-3734



国家食品药品监督管理总局主管



## •新药述评与论坛•

- 481 治疗帕金森精神症新药pimavanserin.....宋品娆, 温利民, 姜锋, 等  
484 ALK抑制剂克唑替尼的专利分析.....徐迪帆, 黄璐, 盛锡军, 等  
489 我国基本药物可及性评估的理论框架.....席晓宇, 马丹丹, 陈飘飘, 等  
494 基于专利视角的糖尿病领域代表性企业新药研发策略对比分析.....刘沛然, 从俊杰, 孟庆海  
499 药品临床试验机构资格认证管理平台建设探讨.....欧阳昭连, 荆淑芳, 范云满, 等

## •新药申报与审评技术•

- 504 药物临床价值评估的主要考虑因素及问题.....刘炳林, 薛斐然

## •重大新药创制专项巡礼•

- 509 从“治脑病”角度探讨糖尿病及其阿尔茨海默病的防治.....赖琼, 张海燕, 杨启悦, 等  
514 浅析 I 期临床试验不良事件及风险管理.....李艳芬, 黄兴, 王瑞华, 等  
519 纳米喷雾干燥技术的特点及其在药物制剂领域中的应用.....陈娟, 杨志强, 张坤, 等

## •综述•

- 525 胆汁酸及受体与肝癌的研究进展.....朱世超, 郑学敏, 周植星, 等  
530 微透析技术在中药外用制剂中的应用.....管咏梅, 肖芳, 金晨, 等  
535 经典途径IKK $\alpha$ 和IKK $\beta$ 在胰岛素抵抗和2型糖尿病中的作用机制及药物治疗.....余美霞, 刘迅, 杜柳涛, 等  
542 玉叶金花化学成分和生物活性的研究进展.....李娟, 赵小芳, 谢扬帆, 等

## •实验研究•

- 548 Liguzinediol乙酰氨基酸双酯前药的设计、合成及生物活性评价.....沈敏哲, 李智, 李伟, 等  
555 淫羊藿苷元微乳制剂对小鼠免疫性血小板减少性紫癜模型的治疗作用.....王辰, 张珂, 李婉, 等  
562 反义寡核苷酸药物流感泰得对大鼠的亚急性毒性观察.....郭明刚, 鲁丹丹, 刘超, 等  
570 氯法拉滨的合成新工艺.....程志刚, 陈亮, 王旭东, 等  
573 马来酸氟吡汀滴丸的药动学研究.....吕晓敏, 孙程, 王冬东, 等  
578 百部新碱口腔崩解片的制备及其质量评价.....易敏, 吴琦, 梁光平, 等  
583 氟脲嘧啶-羟丙基- $\beta$ -环糊精包合物的生物黏附凝胶剂的制备与评价.....王璐璐, 郭慧慧, 黄帅, 等  
588 基于数学模型研究辅料对中药提取物片剂压缩特性的影响.....田倩瑜, 王亚静, 张哲, 等

## •药物安全与合理用药•

- 593 临床药师参与2例丙硫氧嘧啶致抗中性粒细胞胞浆抗体相关性血管炎的病例分析.....向翼, 程庆丰, 朱深银, 等  
598 化疗联合贝伐珠单抗治疗恶性心包积液1例并文献复习.....刘凡, 崔慧娟, 彭艳梅, 等

- 481 A new drug for the treatment of Parkinson's disease psychosis: pimavanserin  
SONG Pin-rao, WEN Li-min, JIANG Feng, *et al*
- 484 Patent analysis for ALK inhibitor crizotinib  
XU Di-fan, HUANG Lu, SHENG Xi-jun, *et al*
- 489 A theoretical framework of essential drug accessibility assessment in China  
XI Xiao-yu, MA Dan-dan, CHEN Piao-piao, *et al*
- 494 Comparative analysis of new drug research and development strategy of representative enterprises in the field of diabetes mellitus based on patent perspective  
LIU Pei-ran, CONG Jun-jie, MENG Qing-hai
- 499 Discussion of building a platform for the qualification of certification management about the drug clinical trials  
OUYANG Zhao-lian, JING Shu-fang, FAN Yun-man, *et al*
- 504 Key considerations and issues of assessment for clinical value of drugs  
LIU Bing-lin, XUE Fei-ran
- 509 Discussion on the prevention and cure of diabetes and its complication of AD from the angle of "treating encephalopathy"  
LAI Qiong, ZHANG Hai-yan, YANG Qi-yue, *et al*
- 514 Analysis on the adverse events and risk management in phase I clinical trials  
LI Yan-fen, HUANG Xing, WANG Rui-hua, *et al*
- 519 The characteristics of the nano spray drying technology and its application in the pharmaceutics fields  
CHEN Juan, YANG Zhi-qiang, ZHANG Kun, *et al*
- 525 Research progress for bile acids with its receptors in hepatocellular carcinoma  
ZHU Shi-chao, ZHENG Xue-min, ZHOU Zhi-xing, *et al*
- 530 Application of microdialysis technique in the external preparations of traditional Chinese medicines  
GUAN Yong-mei, XIAO Fang, JIN Chen, *et al*
- 535 The mechanism of caninal IKK $\alpha$  and IKK $\beta$  in insulin resistance and type 2 diabetes mellitus as well as drug therapy  
YU Mei-xia, LIU Xun, DU Liu-tao, *et al*
- 542 Research progress on the chemical constituents and biological activities of *Mussaenda Pubescens* Ait. f.  
LI Juan, ZHAO Xiao-fang, XIE Yang-fan, *et al*
- 548 Design, synthesis and biological evaluation of liguzinediol acetyl amino acid dual ester prodrugs as promising inotropic agents  
SHEN Min-zhe, LI Zhi, LI Wei, *et al*
- 555 Effects of anhydroicaritin microemulsion formulation on the immunologic boctopenic purpura mice  
WANG Chen, ZHANG Ke, LI Wan, *et al*
- 562 Observation on subacute toxicity of antisense oligonucleotides flutide in rats  
GUO Ming-gang, LU Dan-dan, LIU Chao, *et al*
- 570 New synthetic process of clofarabine  
CHENG Zhi-gang, CHEN Liang, WANG Xu-dong, *et al*
- 573 Study on the pharmacokinetics of flupirtine maleate dropping pills  
LÜ Xiao-min, SUN Cheng, WANG Dong-dong, *et al*
- 578 Preparation and quality evaluation of stemoninine orally disintegrating tablets  
YI Min, WU Yi, LIANG Guang-ping, *et al*
- 583 Preparation and characterization of bio-adhesive vaginal gel containing 5-fluorouracil-HP- $\beta$ -CD inclusion  
WANG Lu-lu, GUO Hui-hui, HUANG Shuai, *et al*
- 588 Research on the effect of excipients on the herb extract compression characteristics base on mathematical models  
TIAN Qian-yu, WANG Ya-jing, ZHANG Zhe, *et al*
- 593 Analysis of 2 clinical pharmacist participated cases of propylthiouracil induced anti-neutrophil cytoplasmic antibodies associated vasculitis  
XIANG Yi, CHENG Qing-feng, ZHU Shen-yin, *et al*
- 598 Treatment for malignant pericardial effusion by chemotherapy combined with bevacizumab: a case report and literature review  
LIU Fan, CUI Hui-juan, PENG Yan-mei, *et al*

Directed by: China Food and Drug Administration  
Sponsored by: China Medical Science Press  
China National Pharmaceutical Group Corp.  
Chinese Pharmaceutical Association  
Editor-in-Chief: SANG Guo-wei  
Board Chairman: SHI Sheng-yi  
Edited by: Editorial Board of Chinese Journal of New Drugs  
Published by: Chinese Journal of New Drugs Co., Ltd.  
Address: Room 1605, No.2 Ocean Cityscape, No.123 Zhongguancundonglu,  
Haidian District, Beijing 100086, China  
Tel: (010)82282300 / 82282326

Fax: (010)82282289  
Website: <http://www.newdrug.cn>  
E-mail: [bianjibu@newdrug.cn](mailto:bianjibu@newdrug.cn)  
Printer: Beijing Kexin Printing Co., Ltd.  
Domestic Distribution: Beijing Post Offices  
Overseas Distribution: China International Book Trading Corp.  
(P.O.Box 399 Beijing, China)  
Domestic Subscription: Local Post Offices  
Periodical Registration: ISSN 1003-3734 CN 11-2850/R  
Publication Date: March 15, 2017  
Copyright: 2017 by Chinese Journal of New Drugs Co., Ltd.

乐松® 贴剂  
局部抗炎镇痛 新选择

重拳出击  
有效镇痛



### 简要处方说明书：

【通用名】洛索洛芬钠贴剂

【规格】每贴7cm\*10cm，含洛索洛芬钠50mg。

【性状】本品为淡褐色至褐色膏体，涂布于背衬层上，膏体表面覆盖透明保护层。

【适应症】用于骨关节炎、肌肉痛、外伤导致肿胀疼痛。

【用法用量】1日1次，贴于患处。

【孕妇及哺乳期妇女用药】尚未确立安全性，建议权衡利弊。

【儿童用药】尚未确立安全性。

【老年用药】注意贴敷部位的皮肤状况。

【药物相互作用】暂无。

【禁忌症】对本品成分有过敏既往史者；患有阿司匹林性哮喘或有其既往史者禁用。

【注意事项】支气管哮喘患者慎用。本品为对症治疗。不得用于损伤皮肤及粘膜、湿疹或发疹部位等。

【不良反应】主要有瘙痒、红斑、接触性皮炎等皮肤症状、胃不适等消化道症状以及ALT、AST等实验室检查值异常。

【贮藏】遮光，密封，不超过25℃保存。

【包装】铝塑复合袋包装。3贴/袋。

【有效期】24个月。

【批准文号】进口药品注册证号：H20140638（50mg/贴）

【国内联系单位】第一三共（中国）投资有限公司

地址：上海市南京西路1717号会德丰国际广场51楼  
邮政编码：200040  
联系电话：400-656-3228  
传真号码：021-60397399  
不良反应报告热线：021-60397322

禁忌症和不良反应具体内容详见说明书  
注意：在处方前，请仔细阅读参阅中国批准的完整说明书。详细处方资料备案。  
本广告仅供医学药学专业人士阅读。 沪药广审(文)第2016040144号



第一三共